Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04812457
Other study ID # UMalagaUEX2021
Secondary ID
Status Completed
Phase Early Phase 1
First received
Last updated
Start date March 6, 2021
Est. completion date June 1, 2022

Study information

Verified date January 2023
Source University of Malaga
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare the efficacy of a postoperative treatment protocol with hyaluronic acid-based ointment compared to the standard protocol (betadine gel) in partial chemical matricectomies with phenol alcohol technique. This will allow to see if the use of hyaluronic acid could help to reduce the healing time and total recovery of this surgical technique


Description:

A randomized controlled multicenter study will be conducted. Subject (n=60) will be adolescent and healthy adults, between 14 and 40 years old, who require and demand surgical treatment of onychocryptosis or stage I or IIa ingrown nail in the participating centers. After acceptance to participate in the study, they will be operated on in a standardized protocol with phenol-alcohol technique. Then they will be randomly assigned into 2 groups, to perform different treatment protocols. The experimental group will receive physiological cures using pure hyaluronic acid (Hialucic®) after the onychocryptosis surgery, while the control group will receive traditional cure (Betadine Gel). The periodicity of cures in both groups will be the same, 48 hours, 6 days, 12 days 16 days and 20 days. For the design of the study, the bases on randomized clinical studies described in CONSORT will be followed. The outcome measurement will be the presence of exudate in each of the cures (carried out at the same post-surgical times), presence or absence of granulation tissue, reduction of inflammation (measured with the circumference of the finger in the eponychium area), cost average treatment protocol, time elapsed until primary healing (when the wound stops staining the bandage) and final surgical discharge (finger without wound or inflammation), referred pain in the finger during the healing period and presence of complications, such like persistent inflammation, infection, etc. PARTICIPANTS Participants will be recruited through the Podiatric Clinic of the University of Extremadura and Lopezosa y Gijon Nogueron clinics in Malaga and Granada SAMPLE´S SIZE CALCULATION The confidence level was established at 95% and the statistical power at 90%. We need a minimum precision value of 3 days (time between cures). The squared variance (S2) is 16, since in a previous pilot study the variance between groups of cures was 4 days The inclusion criteria were as follows: - Patients aged between 14 and 40 years old - Patients with stage I, II, or III onychocryptosis (Kline classification) or Mozena stage I or IIa [7] - Patients with onychocryptosis unilateral or bilateral. - Healthy patients without previous systematic pathologies (diabetes, coagulation or immunological disorders) who require and demand surgical treatment of their pathology in the participating centers and willing to participate in the study. Participants were excluded if any of the following were present: - Onychocyptosis with significant involvement of the hypertrophic labrum - Patients with hyperhidrosis - Severe paronychias - Allergy to any of the substances used in the intervention or in the cures. 2.3 RANDOMIZATION Participants will be divided into two groups: a) experimental or intervention group (hyaluronic acid cures) and b) control group (Betadine Gel cures) by random assignment of sealed envelopes, which will be previously sealed in sequential order. Both the patient and the researcher will be blinded to hide the group to which each patient belongs. 2.4 INTERVENTION For the intervention of unilateral onychocryptosis, the partial matricectomy technique with phenol / alcohol will be carried out. After removal of the affected spicule, basic manual curettage will be performed with a Wolkmann or Martini spoon. Once the matrix has been mechanically removed, the phenol will be applied. Phenol 88% in sterile capsules will be used in the affected canal using a cotton swab for two applications of 30 seconds. Between these two applications, alcohol will be used to dissolve the phenol present in the nail bed. After the last application of phenol, the area will be washed again with alcohol. After the intervention, hyaluronic acid will be applied in the operated canal. A non-stick dressing impregnated with Betadine will be placed and a semi-compression bandage will be applied. A professional not present at the intervention (researcher 2) will proceed to carry out the postoperative cures 48 hours after the intervention. The bandage will be removed, the area will be washed with physiological saline and the drug will be applied according to the group to which it belongs. In the intervention group, an ointment with hyaluronic acid (hyalucic ®) will be used together with a non-stick dressing and a semi-compression bandage to prevent bleeding. In the control group, Povidone Iodine Gel (Betadine Gel®) will be applied following the same procedure. Successive cures will be carried out every 2 days by the healthcare professional, where both groups will be washed with saline solution and a new dose of ointment will be applied as appropriate in each group. hyaluronic acid for cures a maximum of 4 times, to avoid maceration of the wound. the rest of the cures will be with Betadine. Primary healing will be taken as the first variable of surgical results and the definitive discharge time, which will be determined by researcher 2 (who was responsible for the cures) and confirmed by a third evaluator, who will verify the results. 2.5 OUTCOME MEASURE The demographic characteristics of the participants will be age, sex, and onychocryptosis classification according to Kline or Mozena. The variables to be used are: - Dressing application time (time recorded in min). - Presence of exudate (Very Abundant / Abundant / Slight / Absent). - Reduction of inflammation, measured in mm with flexible tape around the eponychium. - Cost (average costs for all materials used per patient in €), - Visual analog scale pain (VAS) - Presence of complications such as infection (noted at the end of treatment or dressing change). - Time elapsed until the primary healing and total healing of the wound (days).


Recruitment information / eligibility

Status Completed
Enrollment 70
Est. completion date June 1, 2022
Est. primary completion date February 1, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 14 Years to 40 Years
Eligibility Inclusion Criteria: - Patients aged between 14 and 40 years old - Patients with stage I, II, or III onychocryptosis (Kline classification) or Mozena stage I or IIa - Patients with onychocryptosis unilateral or bilateral. - Healthy patients without previous systematic pathologies (diabetes, coagulation or immunological disorders) who require and demand surgical treatment of their pathology in the participating centers and willing to participate in the study. Exclusion Criteria: - Onychocyptosis with significant involvement of the hypertrophic labrum - Severe paronychias - Allergy to any of the substances used in the intervention or in the cures.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Hialucic
A professional not present at the intervention (researcher 2) will proceed to carry out the postoperative cures 48 hours after the intervention. The bandage will be removed, the area will be washed with physiological saline and the drug will be applied according to the group to which it belongs. In the intervention group, an ointment with hyaluronic acid (hyalucic ®) will be used together with a non-stick dressing and a semi-compression bandage to prevent bleeding.
Betadine gel
A professional not present at the intervention (researcher 2) will proceed to carry out the postoperative cures 48 hours after the intervention. The bandage will be removed, the area will be washed with physiological saline and the drug will be applied according to the group to which it belongs. In the control group, Betadine Gel will be used together with a non-stick dressing and a semi-compression bandage to prevent bleeding.

Locations

Country Name City State
Spain Eva Lopezosa Reca Málaga

Sponsors (1)

Lead Sponsor Collaborator
University of Malaga

Country where clinical trial is conducted

Spain, 

References & Publications (4)

Andreassi A, Grimaldi L, D'Aniello C, Pianigiani E, Bilenchi R. Segmental phenolization for the treatment of ingrowing toenails: a review of 6 years experience. J Dermatolog Treat. 2004 Jun;15(3):179-81. doi: 10.1080/09546630410026860. — View Citation

Giacalone VF. Phenol matricectomy in patients with diabetes. J Foot Ankle Surg. 1997 Jul-Aug;36(4):264-7; discussion 328. doi: 10.1016/s1067-2516(97)80070-1. — View Citation

Hassel JC, Hassel AJ, Loser C. Phenol chemical matricectomy is less painful, with shorter recovery times but higher recurrence rates, than surgical matricectomy: a patient's view. Dermatol Surg. 2010 Aug;36(8):1294-9. doi: 10.1111/j.1524-4725.2010.01625.x. Epub 2010 Jun 22. — View Citation

Karaca N, Dereli T. Treatment of ingrown toenail with proximolateral matrix partial excision and matrix phenolization. Ann Fam Med. 2012 Nov-Dec;10(6):556-9. doi: 10.1370/afm.1406. Erratum In: Ann Fam Med. 2013 Jan-Feb;11(1):4. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Time elapsed until the primary healing and total healing of the wound We measure the days that the patients wait to see the wound perfectly between 0 days until 300 days from the intervention until 15 weeks late
Secondary Presence of exudate (Very Abundant / Abundant / Slight / Absent). from the intervention until 15 weeks late
Secondary Reduction of inflammation measured in mm with flexible tape around the eponychium from the intervention until 15 weeks late
Secondary cost average costs for all materials used per patient in € from the intervention until 15 weeks late
Secondary Visual analog scale pain Visual analog scale pain between 0 to 100 mm from the intervention until 15 weeks late
Secondary Presence of complications such as infection Noted at the end of treatment or dressing change from the intervention until 15 weeks late
See also
  Status Clinical Trial Phase
Recruiting NCT04586361 - Prospective Analysis of Introperative RegenLab PRP and Hyaluronic Acid in Patients With Knee ACL Tear Phase 4
Not yet recruiting NCT05579522 - Clinical Evaluation of Interdental Papilla Reconstruction Using Injectable Autogenous Fat Versus Hyaluronic Acid Filler. N/A
Recruiting NCT05682833 - Adjunctive Use Of A Novel Hyaluronic Acid/Chlorhexidine Gel In The Non Surgical Treatment Of Periodontitis N/A
Completed NCT06451406 - Hyaluronic Acid Injection in the Glans Penis Versus Selective Serotonin Reuptake Inhibitors for Lifelong Premature N/A
Not yet recruiting NCT05055557 - The Role and Mechanism of O-GlcNAc Glycosylation Modified HAS2 in the Hyaluronic Acid Synthesis in ARDS
Completed NCT05201040 - Evaluate the Safety and Effectiveness of Mannitol-combined Hyaluronan Supplement in the Treatment of Knee OA N/A
Terminated NCT05082480 - Evaluate the Effectiveness of Crosslinked HA on the Adhesion Preventing After Trigger Finger Release Surgery N/A
Not yet recruiting NCT05855070 - Intralesional Hyaluronic Acid and Verapamil Injection in Peyronie's Disease N/A
Not yet recruiting NCT06379997 - Oral Supplementation Compared With Hyaluronic Acid Infiltration in Rotator Cuff Tendinopathies N/A
Recruiting NCT05990049 - Hyaluronic Acid and Free Gingival Graft Healing Phase 3
Recruiting NCT06077981 - Comparison of 0.4% Hyaluronic Acid Solution Versus Hydroxyethylamide Solution in Submucosal Endoscopic Resections N/A
Completed NCT05881330 - ArtiAid® for Knee Osteoarthritis: A Post-market Study N/A
Completed NCT05294562 - China Post-Market Clinical Follow-up of FACILLE®
Completed NCT05935449 - The Clinical Trial of Difference Between Formaderm Lidocaine and Formaderm Dermal Filler Injection N/A
Recruiting NCT05039463 - Efficacy at One Year of Combined Injections of Plasma Rich in Platelets and Hyaluronic Acid in Knee Osteoarthritis
Completed NCT05935501 - Clinical Trial of Cross-linked Hyaluronic Acid Dermal Filler N/A
Completed NCT04569045 - Evaluate the Safety and Effectiveness of Sodium Hyaluronate When Used for the Correction of Nasolabial Folds N/A
Completed NCT05881317 - ArtiAid® Plus for Knee Osteoarthritis: A Post-market Study N/A
Not yet recruiting NCT05962619 - Arthrocentesis Alone Versus Arthrocentesis With Hyaluronic Acid Injection N/A
Completed NCT04599335 - The Evaluation of the Safety and Effectiveness of a Novel Gel-type Sodium Hyaluronate for the Correction of Aging Mid-face N/A